Switch theme
Sign up to access all valuation multiples
Scope Fluidics Spolka Akcyjna focuses on global challenges in health to develop diagnostic and med tech solutions. The company combines the expertise in microfluidic technology with the awareness of the challenges in medical diagnostics. It provides prototyping support for diagnostic services.
2010
35
LTM Revenue $27K
LTM EBITDA $8.1M
$73.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Scope Fluidics has a last 12-month revenue (LTM) of $27K and a last 12-month EBITDA of $8.1M.
In the most recent fiscal year, Scope Fluidics achieved revenue of $0.1M and an EBITDA of -$4.6M.
Scope Fluidics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Scope Fluidics valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $27K | XXX | $0.1M | XXX | XXX | XXX |
| Gross Profit | -$9.4M | XXX | -$0.4M | XXX | XXX | XXX |
| Gross Margin | -35272% | XXX | -266% | XXX | XXX | XXX |
| EBITDA | $8.1M | XXX | -$4.6M | XXX | XXX | XXX |
| EBITDA Margin | 30611% | XXX | -3352% | XXX | XXX | XXX |
| EBIT | $7.7M | XXX | -$7.6M | XXX | XXX | XXX |
| EBIT Margin | 28945% | XXX | -5559% | XXX | XXX | XXX |
| Net Profit | $6.1M | XXX | -$5.0M | XXX | XXX | XXX |
| Net Margin | 23037% | XXX | -3641% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Scope Fluidics's stock price is PLN 152 (or $40).
Scope Fluidics has current market cap of PLN 413M (or $110M), and EV of PLN 277M (or $73.6M).
See Scope Fluidics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $73.6M | $110M | XXX | XXX | XXX | XXX | $2.24 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Scope Fluidics has market cap of $110M and EV of $73.6M.
Scope Fluidics's trades at 537.7x EV/Revenue multiple, and -16.0x EV/EBITDA.
Equity research analysts estimate Scope Fluidics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Scope Fluidics has a P/E ratio of 17.9x.
See valuation multiples for Scope Fluidics and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $110M | XXX | $110M | XXX | XXX | XXX |
| EV (current) | $73.6M | XXX | $73.6M | XXX | XXX | XXX |
| EV/Revenue | 2774.7x | XXX | 537.7x | XXX | XXX | XXX |
| EV/EBITDA | 9.1x | XXX | -16.0x | XXX | XXX | XXX |
| EV/EBIT | 9.6x | XXX | -9.7x | XXX | XXX | XXX |
| EV/Gross Profit | -7.9x | XXX | n/a | XXX | XXX | XXX |
| P/E | 17.9x | XXX | -22.0x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -13.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialScope Fluidics's last 12 month revenue growth is n/a
Scope Fluidics's revenue per employee in the last FY averaged $4K, while opex per employee averaged $0.2M for the same period.
Scope Fluidics's rule of 40 is 98149% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Scope Fluidics's rule of X is 30611% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Scope Fluidics and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | -56% | XXX | XXX | XXX |
| EBITDA Margin | 30611% | XXX | -3352% | XXX | XXX | XXX |
| EBITDA Growth | -260% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 98149% | XXX | -3352% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 30611% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.2M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 5293% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Scope Fluidics acquired XXX companies to date.
Last acquisition by Scope Fluidics was XXXXXXXX, XXXXX XXXXX XXXXXX . Scope Fluidics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Scope Fluidics founded? | Scope Fluidics was founded in 2010. |
| Where is Scope Fluidics headquartered? | Scope Fluidics is headquartered in Poland. |
| How many employees does Scope Fluidics have? | As of today, Scope Fluidics has 35 employees. |
| Is Scope Fluidics publicy listed? | Yes, Scope Fluidics is a public company listed on WAR. |
| What is the stock symbol of Scope Fluidics? | Scope Fluidics trades under SCP ticker. |
| When did Scope Fluidics go public? | Scope Fluidics went public in 2017. |
| Who are competitors of Scope Fluidics? | Similar companies to Scope Fluidics include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of Scope Fluidics? | Scope Fluidics's current market cap is $110M |
| What is the current revenue of Scope Fluidics? | Scope Fluidics's last 12 months revenue is $27K. |
| What is the current EV/Revenue multiple of Scope Fluidics? | Current revenue multiple of Scope Fluidics is 2774.7x. |
| Is Scope Fluidics profitable? | Yes, Scope Fluidics is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Scope Fluidics? | Scope Fluidics's last 12 months EBITDA is $8.1M. |
| What is Scope Fluidics's EBITDA margin? | Scope Fluidics's last 12 months EBITDA margin is 30611%. |
| What is the current EV/EBITDA multiple of Scope Fluidics? | Current EBITDA multiple of Scope Fluidics is 9.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
